ArticleBritish journal of cancer2026
Identification of microRNAs as biomarkers for triage of cervical intraepithelial neoplasia in cervical scrape samples from high-risk HPV-positive women.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) is the fourth leading cause of cancer death in women worldwide. High-risk human papillomavirus (HR-HPV) testing is highly sensitive but lacks specificity for identifying women at risk of progression. Reliable biomarkers are urgently needed to identify HR-HPV-positive women most likely to develop cervical cancer. Aberrant microRNA (miRNA) expression contributes to HPV-driven carcinogenesis and represents a promising diagnostic tool.
methodsCervical scrape samples from HR-HPV-positive women were histologically classified as low-grade (≤CIN1) or high-grade (CIN2/3). Total RNA was extracted and small RNA sequencing performed to identify differentially expressed miRNAs. Bioinformatic analyses included clustering, ROC curves, logistic regression, and functional enrichment. Selected candidates were validated byRT-qPCR in independent samples.
resultsNineteen dysregulated miRNAs distinguished low- from high-grade lesions, six linked to viral and cancer pathways. Three (hsa-miR-501-3p, hsa-miR-1271-5p, hsa-miR-9-5p) were validated by RT-qPCR and showed strong discriminatory capacity. hsa-miR-501-3p reached high diagnostic accuracy (AUC = 0.88), which improved to 0.94 when combined with the others. The validated signature achieved high sensitivity and specificity for detecting high-grade lesions.
conclusionThis pioneering study in Colombia using cervical scrapes demonstrates that miRNAs are potential biomarkers for high-grade cervical lesions and that this clinically relevant, minimally invasive sample routinely collected in screening supports their use.
Identifiers
42552363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.